In summary, we report that penfluridol, a drug for treating schizophrenia in the clinic, can suppress mitochondrial OXPHOS through targeting the SIRT1/PGC-1α axis to reduce ATP production, especially in mutant KRAS-expressing NSCLC cells. This evidence concerns the gene PPARGC1A and non-small cell lung carcinoma.